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Stent implantation represents a major step forward since the
introduction of coronary angioplasty. As indications continue to
expand, better understanding of the early and late biocompatibil-
ity issues appears critical. Persisting challenges to the use of
intracoronary stents include the prevention of early thrombus
formation and late neointima development. Different metals and
designs have been evaluated in animal models and subsequently
in patients. Polymer coatings have been proposed to improve the
biocompatibility of metallic stents or to serve as matrix for drug
delivery and they are currently undergoing clinical studies. The
promises of a biodegradable stent have not yet been fulfilled
although encouraging results have recently been reported. Con-
tinuous low dose-rate brachytherapy combining the scaffolding
effect of the stent with localized radiation therapy has witnessed
the development and early clinical testing of radioactive stents.
The combined efforts of basic scientists and clinicians will un-
doubtedly contribute to the improvement of stent biocompatibility
in the future.
(J Am Coll Cardiol 1998;32:562–71)
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During the last 20 years, major technologic advances have been
achieved and new devices for coronary interventions have been
tested. Among these, stents recently modified standard prac-
tice by affording a highly effective and safe method to tackle
dissections occurring after balloon angioplasty. Two landmark
studies have shown that slotted tube, stainless steel, balloon-
expandable stents could significantly decrease restenosis rates
in selected lesions (1,2). Multidisciplinary efforts have subse-
quently been put into stent research and as a result, new
designs and different materials and coatings have been pro-
posed to further improve the performance of these prostheses.
The purpose of this review is to address some issues of stent
design and materials, to review recent experience with various
stent coatings and biodegradable* stents and to describe recent
research data involving surface modifications to increase bio-
compatibility and possibly reduce neointima formation.
Coronary stents: material and design. Metallic character-
istics, bulk and surface properties, design and chemistry are all
important factors to consider in the conception of an optimal
stent. Materials to be used as stent backbone must fulfill
stringent physical, mechanical and chemical properties. The
metal of an expandable stent must have enough plasticity to
remain at the required size when deployed. Self-expanding
stents, in addition, must be prepared from metals with suffi-
cient elasticity so they can be compressed and then expanded
and retain sufficient radial hoop strength to prevent vessel
recoil or closure once in place (3). First-generation coronary
stents were made of surgical grade stainless steel or tantalum,
although several investigators have also suggested the use of
temporary or permanent nitinol stents due to the superelastic
and thermal shape memory properties of that alloy (4–6).
Among chemical characteristics, corrosion properties are
paramount. Formation of a surface metal oxide-film retards
corrosion, and for some metals, such as chromium and tita-
nium, this passivation is highly effective.
However, saline liquids (such as blood) will destabilize the
oxide layer on many metals. Although not yet investigated with
stents, it has been shown that corrosion particles may migrate
from metallic implants to other parts of the body (3). To date,
long-term results with stainless steel or tantalum coronary
prostheses do not suggest any signs of local or distant toxicity
(7). The most recent available stents are manufactured in 316L
stainless steel, with L indicating the low (0.03% weight) carbon
content. This alloy is predominantly iron (60% to 65%) mixed
with chromium (17% to 18%) and nickel (12% to 14%) (8).
The chromium content affords a very good corrosion protec-
tion in addition to contributing to strength and hardness (8,9).
Thus, 316L stainless steel provides good resistance to corro-
sion, and excellent mechanical properties but biocompatibility
remains limited by the thrombosis issue (3,8,9). Nickel
(>55%)-titanium (>45%) (Nitinol) stents may offer some
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advantages that have not yet been fully explored in the clinical
setting (9). Nitinol alloy has also proved to have good early
biocompatibility. Some concern exists that nickel leakage from
these alloys could lead to immunogenic reactions (8,10,11).
Tantalum confers several theoretical advantages over stainless
steel in terms of radiopacity, biocompatibility, mechanical
properties and lack of ferromagnetism. It is regarded as a
biologically inert material. After implantation, the tantalum
stent wire undergoes oxidation, resulting in an oxide that is
very stable and extremely resistant to degradation (3). In the
circulation, the thin layer of inert tantalum peroxide creates an
electrically negative charge that could reduce adhesion of
negatively charged platelets (12). However, in clinical practice,
tantalum has not been shown to decrease stent thrombosis
compared with stainless steel stents. This may be partly due to
the activation of the coagulation cascade by negatively charged
surfaces (13). Therefore, whether the metallurgic properties
may confer an advantage in vivo is still unknown. Scott et al.
(14) found no difference in platelet deposition and fibrin
accumulation between identical coil stents made of tantalum
or stainless steel in baboon arteriovenous shunts and in
porcine coronary arteries. Rogers and Edelman (15) compared
vascular injury, thrombosis rates and neointima formation
between stainless steel slotted tube (Palmaz-Schatz) and stain-
less steel corrugated ring stents (Multilink) in rabbit iliac
arteries. These two stents have distinct designs but identical
metals and metal-to-surface ratios. Overall neointima forma-
tion was proportional to vessel injury and corrugated ring
stents created 42% less arterial injury and 38% less neointimal
hyperplasia than slotted tube stents. Polymer coating (Throm-
boshield) had no effect on vessel injury or neointima formation
but significantly decreased thrombosis rates. Altering the stent
surface with a polymer coating virtually eliminated thrombotic
occlusion in corrugated ring stents and significantly reduced
thrombosis rates in coated versus uncoated slotted-tube stents
(8% vs. 42%, respectively). Barth et al. (16) performed paired
comparisons of vascular wall reactions after implantation of 3
different stents in dog peripheral arteries. Neointima forma-
tion was significantly higher with Strecker stents than with
Wallstent or Palmaz stents. Sheth et al. (17) described less
thrombosis and vessel injury after implantation of slotted tube
nitinol stents in rabbit carotid arteries compared with Palmaz-
Schatz stents. In an attempt to separate the multiple factors
involved in stent performance, Fontaine et al. (18) compared
similarly designed tantalum coil stents with different rigidity.
The more rigid stents induced more vessel injury and created
more neointima than the flexible design. Buchwald et al. (19)
compared regular and short-wave Wiktor stents implanted in
minipig coronary arteries. Although neointimal area was re-
duced at 4 weeks in the short-wave group, no difference
subsisted in neointimal or lumen area between the 2 groups at
12 weeks. Therefore, the increased metal mass (15%) associ-
ated with the short-wave design did not lead to increased
neointima formation. Many factors such as blood rheology,
longitudinal flexibility, metal hoop-strength and coverage may
interfere with and complicate the objective evaluation of stents
with different designs.
Furthermore, surface treatment has also been shown to
modify the performance of stents. Sheth et al. (20) compared
the effects of mechanical polishing to decrease surface irregu-
larities on thromboses in an ex vivo porcine arteriovenous
shunt model. Polished nitinol slotted-tube and Palmaz-Schatz
stents exhibited a drastic reduction in thrombus formation
compared with unpolished nitinol stents. De Scheerder et al.
(21), using electrochemical polishing of stainless steel stents,
showed a significant reduction in early thrombosis in a rat
arteriovenous shunt model and less neointima formation in a
pig coronary model compared with untreated stents. Other
investigators have also tested noble metal coatings to improve
the corrosion properties (22,23). However, no distinct advan-
tages in terms of thrombus or neointima formation were found
between metal coatings by galvanization or ion implantation
compared with uncoated stents. Thus, experimental data sug-
gest that stent design and surface properties may influence
early and late results of stenting in animal models. Ongoing
randomized trials comparing various stent designs will soon
confirm whether this translates into different clinical outcomes.
Polymer coatings (Table 1). Polymers are long-chain mol-
ecules that consist of small repeating units (8). Several poly-
mers with previous medical or dental use have been evaluated
to cover stents or to coat stent struts.
Nonbiodegradable synthetic polymers. Van der Giessen et
al. (24) compared thrombosis rates and neointima formation
using uncoated and coated Wallstents with Biogold (Plasma
Carb Inc.). Despite suppression of early thrombosis with the
coating, neointima formation remained similar in both groups
after 12 weeks. A large group of investigators have evaluated 3
synthetic nonbiodegradable coatings partially covering coil
tantalum stents (25). Three different nonsterile polymers were
implanted in a pig coronary model: polyurethane, poly (di-
methyl) siloxane (silicone) and polyethylene terephtalate (Da-
cron). All but one of the 20 silicone-coated stents remained
patent at 4 weeks. All polymers elicited intense inflammatory
responses with presence of multinucleated giant cells and
macrophages surrounding proteinaceous debris and thrombus
remnants. De Scheerder et al. (26) compared 2 different
polymer coatings of stainless steel slotted tube stents in normal
porcine coronary arteries. Stents were coated with either a
biodegradable poly(organo)phosphazene (POP) or a biostable
polyurethane. Although 3 of 6 pigs with uncoated stents died of
acute stent occlusion, only one of four POP-coated stents was
found occluded at follow-up angiography. No difference in
neointima proliferation was found between bare and polyure-
Abbreviations and Acronyms
PEO/PBTP 5 polyethylenoxide/polybutylene terephtalate copolymer
PLLA 5 poly-l-lactic acid
PHBV 5 polyhydroxy-butyrate-valerate copolymer
POP 5 poly(organo)phosphazene
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thane stents. However, in the POP-coated stent group, severe
intimal proliferation of histiolymphocytic tissue was noted.
Fontaine et al. (27) compared platelet adhesion between
uncoated and polyurethane-coated tantalum stents implanted
in a swine arteriovenous shunt. Radiolabeled platelet accumu-
lation in the uncoated stent group was already more severe
after 5 min and remained higher after 60 to 120 min. In rabbit
carotid arteries, Rechavia et al. (28) observed identical tissue
reaction between polyurethane-coated and uncoated nitinol
stents. Chronos et al. (29) used a copolymer of methacryl-
phosphorylcholine and laurylmethacrylate to coat stainless
steel stents. In a baboon arteriovenous shunt model, they
observed an early decrease in platelet deposition at 60 and
120 min compared with bare stents. Subsequently, Malik et al.
(30) evaluated phosphorylcholine (a component of cell mem-
brane) or cross-linked phosphorylcholine coated on stainless
steel stents in a pig coronary model. No stent thrombosis
occurred in any group and there was no excess neointima
formation in coated versus uncoated stents. Identical results
have been obtained in rabbit iliac arteries with phosphotidyl-
choline by Nordrehaug and colleagues (31). Amon et al. (32)
used a newly designed tantalum stent with a silicon carbide
coating. In vivo testing in a pig model showed the absence of
thrombus formation. Ozbek et al. (33), using the same coating
applied on stainless steel stents reported the first clinical use in
bail-out stenting. Among 44 patients who received 58 silicon-
carbide coated stents, 21% (9 of 42) had restenosis at 6-month
follow-up and stent thrombosis was suspected in two patients.
Thus, these results do not seem to suggest a clinical advantage
for these silicone-carbide coated stents. Therefore, it remains
unclear whether any polymer coating may improve the stent
biocompatibility per se, but recent data suggest that some
polymers such as polyurethane or phosphorylcholine could
serve as effective drug delivery systems.
Biodegradable synthetic polymers. Van der Giessen et al.
(25) studied 5 polymer-coated stents implanted in pig coronary
arteries. Polyglycolic/polylactic acid copolymer, polycaprolac-
tone, polyhydroxy-butyrate/valerate copolymer (PHBV), poly-
Table 1. Polymers Used as Stent Coatings
Author (ref) Stent Material Polymer Biodeg.
Thickness
(mm) Model
Van Der Giessen et al. (24) Wallstent Stainless steel Biogold No — Pig coronary
Van Der Giessen et al. (25) Wiktor Tantalum PGLA Yes 75–125 Pig coronary
PCL Yes
PHBV Yes
POE Yes
PEO/PBTP Yes
PUR No
SIC No
PETP No
de Scheerder et al. (59) Wiktor Tantalum POP No 20 Pig coronary
de Scheerder et al. (26) NA Stainless steel POP No 23 Pig coronary
PUR
Fontaine et al. (27) Fontaine-Dake Tantalum PUR No — Pig shunt
Rechavia et al. (28) NA Niti PUR No — Rabbit carotid
Chronos et al. (29) NA NA MPC/LM No — Arteriovenous baboon shunt
Malik et al. (30) Dyvisio Stainless steel PC No — Pig coronary
XL-PC
Nordrehaug et al. (31) NA Stainless steel PC No — Rabbit iliac
Amon et al. (32) NA Tantalum Silicone carbide No — Pig femoral
Ozbek et al. (33) NA Stainless steel Silicone carbide No — Human coronary
Lincoff et al. (34) Wiktor Tantalum PLLA Yes 11–27 Pig coronary
Schwartz et al. (35) Wiktor Tantalum PPE — — Pig coronary
Holmes et al. (36) Wiktor Tantalum FIB Yes 120 Pig coronary
PUR No 70–120
Kipshidze et al. (38) NA Titanium FIB Yes 40 6 6 Dog iliac artery
Barber et al. (37) Palmaz-Schatz Stainless steel FIB Yes 40 6 6 Dog iliac artery
Lambert et al. (57) Harts Niti PUR No 50 Rabbit carotid
Cox et al. (53) Coil Tantalum CEL Yes — Pig coronary
Folts et al. (69) Palmaz-Schatz Stainless steel PSNO/BSA Yes 80–1000 Pig carotid
Prietzel et al. (63) Palmaz-Schatz Stainless steel PLLA Yes 10 Pig coronary
Aggarwal et al. (66) Cook Stainless steel CEL Yes 30 Rabbit iliac
Biodeg. 5 biodegradable; CEL 5 cellulose; COLL1LAM 5 collagene/laminin; FIB 5 fibrin; H 5 heparin; MPC/LM 5 methacrylphosphorylcholine/
laurymethacrylate; NA 5 not available; Niti 5 nitinol/titanium; PC 5 phosphorylcholine; PCL 5 polycaprolactone; PEO/PBT 5 polyethyleneoxide/polybutylene
terephtalate; PETP 5 polyethylene terephtalate; PGLA 5 polyglycolic/lactic acid; PHBV 5 polyhydroxybutyrate/valerate; PLLA 5 poly-l-lactic acid; POE 5
polyorthoester; POP 5 polyorganophosphazene; PPE 5 polyphosphate ester; PSNO/BSA 5 polynitrosated nitric oxide albumin; PUR 5 polyurethane; SIL 5 silicone;
XL-PC 5 cross-linked phosphorylcholine.
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orthoester and polyethyleneoxide/polybutylene terephtalate
copolymer (PEO/PBTP) were used as strips covering 90 de-
grees of a Wiktor stent circumference. In contrast to similar
studies using nonbiodegradable polymers, 3 of 7 stents with
PHBV and 3 of 10 with PEO/PBTP occluded within hours
after implantation. A wide range of inflammatory response was
also demonstrated. Lincoff et al. (34) evaluated low (80 kD)
and high (321 kD) molecular weight poly-l-lactic acid (PLLA)
coated onto Wiktor stents again in pig coronary arteries. In the
group with low molecular weight PLLA, severe acute and
chronic signs of inflammation were recognized with a variable
destruction of the vessel architecture. In contrast, in the group
with high molecular weight PLLA (slower degradation), there
was no evidence of acute or chronic inflammation, and the
neointima was similar to that noticed in the control group. A
single preliminary study reported no thrombosis and little
inflammation after polyphosphate ester– coated tantalum
stents were implanted in pig coronary arteries (35). Among
these biodegradable polymers, PLLA remains high on the list
to serve as a temporary matrix for drug release.
Natural coated and covered stents. Natural products offer
the theoretical advantage of minimizing the inflammatory
response. Holmes et al. (36) compared fibrin-covered with
polyurethane-covered tantalum stents in a pig coronary artery
model. Polymerization of fibrin produced a film completely
encasing the stent. In addition, fibrin-covered stents were
soaked in a heparin solution for 3 hours. In the other group,
stents were covered with biostable medical grade polyure-
thane. Three of 34 fibrin-covered stents occluded within 48
hours. After 4 weeks, all stents were endothelialized. In
contrast, in the group with polyurethane covering, 6 of 12
stents occluded within 48 hours. In addition, after 4 weeks,
neointimal proliferation in the group with polyurethane coat-
ing completely obliterated the lumen of the remaining stents.
Histology documented an intense foreign-body reaction with
multinucleated giant cells. Baker et al. (37) using a similar
fibrin coating on self-expanding titanium stents and balloon-
expandable Palmaz-Schatz stents, reported a significant reduc-
tion in platelet deposition after 2 hours in an in vitro model.
Subsequently implanted in canine iliac arteries, 3 of 7 uncoated
stents thrombosed after 8 weeks, whereas no coated stent
presented signs of thrombosis. In addition, foreign body reac-
tion was observed in 2 uncoated stents but not in fibrin-coated
stents. Endothelial coverage was also higher in the fibrin-
coated group, suggesting that fibrin could also allow rapid
endothelialization of the stent struts (38). Stefanidis et al. (39)
introduced the concept of a conventional stent completely
covered by an autologous vein or arterial graft. In a pig iliac
artery model, they inserted 27 regular or vein-covered stents.
Two uncovered stents developed subacute thrombosis. With a
follow-up extending up to 6 months, covered stents showed
only minimal hyperplasia (39). These results prompted the
investigators to use the same technique in patients and prelim-
inary clinical results are encouraging (40,41). Because of its
relative complexity, the potential long-term benefit will be the
primary factor that will determine the place of this technique.
Heparin-coated stents (Table 2). Bonan et al. (41) were
first to use heparin-coated (a preliminary version of Carmeda
coating) zig-zag stents in canine coronary arteries. Neither
thrombosis nor neointima formation was different between
coated and uncoated groups. Several preliminary reports,
however, suggested that heparin coating could reduce early
thrombosis (42–44). The Rotterdam group reported experi-
mental and early clinical results with heparin-coated (Car-
meda) Palmaz-Schatz stents (45,46). In their experimental
series, stent thrombosis occurred in 37% of pigs receiving
uncoated stents, whereas no thrombosis was seen in any coated
stent with either moderate or high heparin activity. After 4
weeks, histomorphometric analysis showed a slight but signif-
icant increase in neointimal thickness in the group with highest
heparin activity. However, after 12 weeks, the difference was
no longer significant. Heparin coating induced a decreased
endothelial cell covering of the coated stents, possibly by an
effect of heparin on cell attachment and growth. The Carmeda
coating also appears to be highly effective in reducing platelet
deposition when stents are not completely deployed (47).
Using heparin-bonded tantalum coil stents, Chronos et al.
(48,49) showed similarly less early thrombosis and subsequent
Table 2. Heparin-Coated Stents
Author (ref) Model Stent Coating Control
Thrombosis
Reduction
Neointima
Reduction
Bonan et al. (41) Dog coronary Zig-Zag NA Bare stent No No
Stradienko et al. (42) Rabbit iliac Palmaz-Schatz — Bare stent Yes —
Bailey et al. (43) Rabbit iliac Palmaz-Schatz Proprietary Bare stent Yes No
Sheth et al. (44) Rabbit carotid Harts SPUU-PEO-hep Bare stent Yes —
Hardhammar et al. (45) Pig coronary Palmaz-Schatz Carmeda Bare stent Yes No
Serruys et al. (46) Human coronary art. Palmaz-Schatz Carmeda — Yes —
Chronos et al. (47) Baboon carotid Cordis NA Bare stent Yes Yes
Chronos et al. (48,49) Baboon A-V Palmaz-Schatz Carmeda Bare stent Yes —
Zidar et al. (50,51) Dog coronary Cordis NA Bare stent — No
de Scheerder et al. (52) Pig coronary Self designed Duraflow Bare stent Yes No
Jeong et al. (54) Porcine carotid Wallstent NA Bare stent Yes NA
Vrolix et al. (56) Human coronary art. Wiktor Hepamed — — —
Art. 5 artery; A-V 5 arteriovenous; NA 5 not available; SPUU-PEO-hep 5 polyurethaneurea-polyethylene oxide-heparin.
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neointima formation in baboon carotid arteries. In contrast,
Zidar et al. (50,51) implanted heparin-bonded tantalum coil
stents in dog coronary arteries and found no difference in early
thrombosis or neointima formation between coated and un-
coated stents. De Scheerder et al. (52) performed a detailed
experimental study to evaluate the immediate and delayed
effects of heparin coating. After 30 min in a rat arteriovenous
shunt model, thrombus weight, radiolabeled platelets and
fibrinogen were significantly reduced in the Duraflo II coated
stent group (52). However, when subsequently implanted in
pig coronary arteries, there was no reduction in neointima
proliferation in the group with heparin coating compared with
control stents. Cox et al. (53) evaluated the potential of
heparin release from a cellulose-coated coil stent to reduce
neointima formation. In porcine coronary arteries, there was
no significant difference at 4 weeks between coated and
uncoated stents. Jeong et al. (54) evaluated heparin release
from coated Wallstents in a porcine carotid model. After 1
week, all uncoated stents were occluded, whereas all coated
stents remained widely patent. Therefore, in animal models,
various heparin coatings have been shown to be effective in
reducing thrombosis, although a beneficial effect on neointima
formation remains to be established. Serruys et al. (46) re-
ported initial clinical experience with Carmeda heparin-coated
Palmaz-Schatz stents. Overall, this study showed no stent
thrombosis, and restenosis rates remained low, decreasing
from 15% in the group with conventional anticoagulation to
6% in patients taking a combination of ticlopidine and aspirin.
In the recently completed Benestent II trial comparing
heparin-coated stents with balloon angioplasty, 413 patients
received a stent and thrombosis occurred in only 1 case (55).
Vrolix et al. (56) also reported preliminary results with a
heparin covalent bound (Hepamed) Wiktor stent in 100 pa-
tients. Given the better stent deployment technique and the
clinical effectiveness of the ticlopidine-aspirin regimen, both of
which helped to dramatically reduce stent thrombosis, the
exact role of heparin coating for stents remains to be estab-
lished.
Drug-eluting stents (Table 3). Much interest has been
focused on loading a drug onto a stent to limit the early
thrombogenicity and late neointima formation. Drugs may be
released by diffusion mechanisms or during polymer break-
down. Lambert et al. (57) by using forskolin loaded into a
polyurethane (Tecoflex)-coated nitinol stent, reported a de-
crease in thrombosis in rabbit carotid arteries. The same group
compared drug release between forskolin and etedrinate (58).
Levels of etedrinate in the vessel wall peaked at 24 hours and
remained high up to 72 hours after placement. Levels of
forskolin peaked within 2 hours of stent placement but rapidly
fell during the first 24 hours. About 50% of the original
etedrinate remained in the stent at 72 hours compared with
about 5% of forskolin at 24 hours. Ratios of drug levels in the
vessel wall to that in blood peaked at 6,000 for etedrinate and
at 780 for forskolin. This study confirmed the feasibility and
efficiency of the concept of a drug-eluting stent and demon-
strated the variability in release kinetics according to the
chemical characteristics of the selected compounds. De
Scheerder et al. (59,60) showed an improved biocompatibility
of POP coating by loading the polymer with methylpred-
nisolone or angiopeptin. Cellulose ester has been used in one
study as a coating for tantalum stents with heparin and/or
methotrexate bound to the polymer (53). In porcine coronary
arteries, there was no difference in neointima formation be-
tween drug-coated and uncoated stents. Lincoff et al. (34)
Table 3. Drug-Eluting Stents
Author (ref) Polymer Drug Amount Release/Kinetics Control
Thrombosis
Reduction
Neointima
Reduction
Lambert et al. (57) PUR Forskolin 1.58 mg 95% in 24 h — Yes —
Dev et al. (58) PUR Forskolin 1.5 mg 95% in 24 h — — —
Etedrinate 2.8 mg 50.5% in 72 h
de Scheerder et al. (59,60) POP Methylprednisolone 300 mg 86% in 24 h POP stent — Yes
Cox et al. (53) CEL H, Metho,
H1Metho
— — Bare — No
Lincoff et al. (34) PLLA Dexamethasone 0.8 mg .50% in 2–3 d PLLA — No
Bare stent
Eccleston et al. (61) PLLA Colchicine 3.96 mg 50% in 28 d — — —
0.99 mg ,10% in 28 d
Schmidmaier et al. (64) PLLA PEG-hirudin PG12 — 52.8% in 30 d Bare stent Yes —
11.8% in 30 d
Alt et al. (62–65) PLLA PEG-hirudin PG12 10 mg — Bare stent — Yes
2 mg —
Aggarwal et al. (66) CEL IIb-IIIa inhibitors 60% in 14 d CEL 6 anti-CMV Yes No
Aggarwal et al. (67) CEL IIb-IIIa-UK — — CEL Yes —
Folts et al. (69,70) PSNO/BSA NO — — Bare stent Yes Yes
Baker et al. (71) FIB RGD — — Bare stent — Yes
Santos et al. (72) PLLA L 703,801 40 w % — PLLA No —
Bare stent Yes —
Metho 5 methotrexate; PEG 5 polyethylene glycol; UK 5 urokinase; other abbreviations as in Table 2.
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loaded dexamethasone onto a PLLA matrix that were coated
on Wiktor stents. In a low molecular weight PLLA group,
dexamethasone reduced the inflammatory response observed
in the PLLA group, whereas there was no difference in
neointima formation between polymer-coated and bare stents
in the high molecular weight PLLA group. At 28 days, the
tissue concentration in dexamethasone was still 3,000 higher
than in the blood, confirming the possibility of slow drug
release from a polymer matrix coated on a stent. Eccleston et
al. (61), using the same model-eluting colchicine, also obtained
similar results at 28 days. More recently, other investigators
using PLLA matrix loaded with prostacyclin and PEG-hirudin
coated onto stainless steel stents described less early thrombo-
sis and neointima formation in porcine coronary arteries than
in uncoated stents (62–65).
Aggarwal et al. (66,67) showed decreased early stent throm-
bogenicity using cellulose matrix loaded with glycoprotein
IIb-IIIa inhibitors or a complex of glycoprotein IIb-IIIa uroki-
nase. No reduction in neointima formation was subsequently
demonstrated. However, recent data showed that increased
loading could be achieved, and it is thus possible that higher
local doses can produce a greater biological effect (68). Folts et
al. (69,70) used a polynitrosated albumin nitric oxide donor
coated onto Palmaz-Schatz stents that were implanted in pig
coronary arteries. Preliminary results suggest an early decrease
in thrombosis and less neointimal hyperplasia. Baker et al.
(71), using a fibrin-covered peak stent loaded with an arginine
glycine aspetic acid peptide in an atherosclerotic rabbit model
described significantly less smooth muscle cell proliferation,
inflammation and neointima formation in the coated group.
Santos et al. (72) used a composite polymer-metal stent loaded
with a nonpeptide tirofiban analog and showed a significant
reduction in platelet deposition after 2 h compared with bare
stents in canine coronary arteries. Although the concept of a
drug delivery stent is appealing, the challenges to define the
right pharmacologic agent and its release kinetics further
complicate the polymer issues.
Polymeric stents (Table 4). The group from the Mayo
Clinic first reported initial results using a Dacron tubing mesh
self-expanding stent (73). Two animals killed after 24 hours
confirmed the correct mechanical stent deployment within the
coronary vessel. However, all animals killed 4 to 6 weeks after
implantation showed a stent occluded by neointimal prolifer-
ation. In addition, there was a marked chronic foreign body
inflammatory response with lymphocytes, eosinophils and gi-
ant cells. In contrast, the Rotterdam group, using a similar
stent implanted in peripheral porcine arteries, described
higher patency rates at 4 weeks (74). Histologic analysis
displayed complete endothelial cell coverage and minimal
intimal thickness. A foreign body inflammatory response was
noted in the neointima of all vessels and additional inflamma-
tion was noted in the media of the occluded vessels. It is
therefore possible that a contaminant was present in the
nonsterilized stents used by the group at the Mayo Clinic.
Investigators at Kyoto University developed a biodegradable
stent in polyglycolic acid. All stents were successfully im-
planted in 15 dogs (75). Fresh thrombus was present in some
struts at 3 h. Endothelialization of the stent surface occurred
between 2 and 8 weeks. However, at 1 and 2 weeks, stent
degradation began to occur and foreign body reaction was
recognized. Zidar and colleagues (76) at Duke University have
accumulated a wide experience in the development of biode-
gradable stents. Using PLLA designs, their stents have shown
promising in vitro mechanical properties. In vivo testing in dog
femoral arteries confirmed excellent scaffolding properties.
The degradation was nearly complete by 9 months with
minimal inflammatory response. To assess thrombogenicity
and biocompatibility, 11 polymeric stents, sterilized by poly-
ethylene oxide, were implanted after 5 minutes of heparin
soaking, in a canine femoral artery model. Only 2 stent
occlusions were observed due to traumatic implantation. After
18 months, limited neointima formation was present, but there
was no chronic inflammatory response. Bier et al. (77) devel-
oped bioabsorbable stents in collagen I. Preliminary in vitro
data showed that most of these stents could be expanded
against porcine arteries when correctly matched to vessel size.
Gregory and Grunkemeier (78) evaluated an elastin-based
material as a means to seal the artery. Absorption of the
Table 4. Polymeric Stents
Author (ref) Design
Self-Expanding
Balloon-
Expandable Polymer Model Evaluation Remarks
Murphy et al. (73) Mesh Auto PETP Porcine coronary 24 h, 4–6 w All stents occluded at 6 w
van der Giessen et al. (74) Mesh Auto PETP Porcine periph. 4 w 7/8 patent
Susowa et al. (75) Knitted Balloon PGA Dog coronary 3 h, 1 w, 2 w, 8 w 15/15 patent at 3 h
Zidar et al. (76) Diamond braided Auto PLLA Dog femoral 2 h, 2 d, 4 d, 1 w,
2 w, 12 w, 18 mo
10/11 patent at 18 mo
Bier et al. (77) — Balloon Collagen I In vitro — —
Gregory et al. (78) Sheet-tube Laser energy Elastin Porcine aorta — —
Gao et al. (79) Film — PCL/D,L PLA Porcine carotid 1 mo, 2 mo —
Landau et al. (80) Tubular coil Balloon PLLA-PCL Rabbit carotid
arteries
5 d Carriers for adenovirus
vectors
PCL/D,L-PLA 5 polycaprolactone/D,L-lactic acid; periph 5 peripheral arteries; PETP 5 polyethylene terphtalate; PLLA/PCL 5 poly-l-lactic acid/
polycaprolactone; other abbreviations as in Table 2.
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material into porcine arterial wall was obtained using thermal
bonding with laser energy. Gao et al. (79) developed a
balloon-expandable biodegradable stent made of a copolymer
of coprolactone and D,L lactide impregnated with heparin.
This stent could withstand collapse pressures of 300 to
700 mm Hg at 38°C. After preheating at 51°C, stents were
implanted in mini-swine carotid arteries. No thrombosis or
foreign body reaction was noticed after 2 months. Recently,
Landau and his group (80) developed coil and tubular stents in
copolymers of poly-l-lactic acid and polycoprolactone. They
served also as carriers for recombinant adenovirus vectors and
were implanted in rabbit carotid arteries. Clearly, the efforts to
develop a fully biodegradable stent have been slowed down by
the technical complexities and by the positive long-term results
of metallic stents. The concept, however, together with the
possibility to deliver locally large amounts of drug for an
extended period of time remains appealing.
Endothelial cell seeding. Another interesting approach is
to provide a natural coating by using genetically engineered
endothelial cells. This technique has previously been used for
endovascular graft coatings. In addition, these cells may be
genetically modified to generate increased local fibrinolytic
activity (81,82). However, initial results were marked by lim-
ited cell retention after stent expansion and pulsatile flow
exposure (82,83). To overcome some technical limitations of
cells seeding, Bailey et al. (84) used local delivery of endothe-
lial cells after stent implantation in rabbit iliac and porcine
coronary arteries. After 4 h, both models displayed a large
number (.75%) of attached endothelial cells onto implanted
stents. By 14 days, endothelial cell coverage was .90% in both
treated and untreated segments. Interestingly, it has recently
been shown that local delivery of vascular endothelial growth
factor165 could increase endothelial regeneration after vessel
injury (85). Van belle et al. (86) showed that a single dose of
vascular growth factor administered locally could enhance
endothelial regeneration after stent implantation in rabbit iliac
arteries. Moreover, this accelerated endothelialization was
correlated with a decrease in thrombosis and intimal thicken-
ing after 28 days (86).
Radioactive stents. Besides the use of single doses of
gamma or beta rays delivered at high dose rates by intravas-
cular catheters, radioactive stents present the radiobiological
advantage of delivering radiation at continuous low-dose rates
(87). Using stents radioactivated by particle bombardment,
Herhlein et al. (88) showed a significant reduction in neointima
formation in a rabbit iliac artery model, despite the fact that
extended follow-up revealed that neointima formation was
only delayed in the low-activity stent groups. Later, the same
group and investigators at Walter Reed Army Medical Center
developed a beta-emitting stent by ion implantation of 32P
(89,90). Studies in pig coronary arteries and rabbit iliac arteries
confirmed earlier positive results, although they also noticed
delayed reendothelialization of the stented segments and
increased neointima formation with certain radioactivities
(89,90). Ion implantation of noble metals has been proposed to
improve the corrosion properties of metal alloys (8,23). How-
ever, to obtain the required initial radioactivity with an isotope
such as 32P, would raise the quantity of phosphorus above the
recommended maximum limit of 316L stainless steel (91). As
a consequence, the corrosion properties of the resulting stent
surface would be changed. Thus, it is possible that the surface
characteristics of 32P ion-implanted or particle bombarded
Palmaz-Schatz stents would be modified, leading to reduced
long-term biocompatibility. Another alternative would be to
use an eluting system to deliver a chosen isotope from a stent
platform (92).
Discussion
Biocompatibility has evolved from the previous notion of inert
material to a more recent concept based on the ability of a
material to perform with an appropriate host response in a
specific environment (93). Stent implantation adds to tissue
compatibility the enormous challenge of hemocompatibility.
As we have described, there are several important factors
involved in the design of an optimal coronary stent. Most of the
mechanical properties are related to the bulk characteristics of
the metal or polymer, and those related to biocompatibility are
linked to surface properties. Early biocompatibility problems
with stents are associated with thrombosis, inflammation and
neointima formation. Late problems with stents can be divided
in two broad categories: mechanical failure due to material
fatigue resulting from the considerable stress imposed to stents
by cardiac contractions, and chemical failure where corrosion
or depolymerization can release potential toxic substances
such as nickel, degradation products or contaminants (8,94).
To date, long-term clinical follow-up of first-generation stents
has not revealed signs of mechanical failure or toxicity, al-
though some longer stent designs showed early fatigue when
implanted in animal models and during in vitro testing (un-
published results).
Stent implantation leads to greater vessel injury than bal-
loon dilatation and can be followed by inflammation, wound
healing and sometimes foreign body reaction. Recent data
suggest that the stent design itself may influence the extent of
injury (15,17). Metallic stents have elicited a rather limited
inflammatory response, whereas coated and polymeric stents
have shown more severe responses with histiolymphocytic
infiltrates, macrophages and giant cells typical of foreign body
reaction (25,26). Reports, however, suggest that this inflam-
matory response can be modulated by drug release or polymer
modification. In addition, the accumulation of inflammatory
cells may stimulate growth factor and cytokine release and in
turn promote neointima formation. Drug eluting stents could
therefore provide an ideal tool to limit the inflammatory
reaction and possibly the neointima formation.
The basic tenet of blood-stent interactions is that circulat-
ing cells do not react directly with the coating or the metallic
stent surface (8,13,95). Within minutes after stent implanta-
tion, soluble proteins will adhere to it and rapidly form a
monolayer at the surface of the foreign material. It is therefore
fundamental to understand, at the molecular level, the dy-
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namic process that regulates protein adsorption. Indeed, pro-
teins will adhere according to their plasma concentrations but
also depending on their surface affinity (13,95). Therefore,
there will be a competition between numerous proteins to
adhere to the foreign surface. Some surfaces may preferen-
tially absorb albumin, whereas others will tie fibrinogen. The
former may promote passivation of the stent surface while the
latter may lead to thrombus accumulation. Protein adhesion
leads to conformational changes in the protein structure
initiating cell adhesion, whereas soluble proteins do not inter-
act with circulating cells (13,95). This field is currently under
active investigation, especially since the discovery of the inte-
grin family.
Heparin coatings have been developed to provide perma-
nent fixation or slow release from the material surface (8).
There are basically three different approaches to achieve
heparin coating. First, heparin may be bound by ionic interac-
tion (49). Then, heparin is slowly released and interacts with
antithrombin III to neutralize thrombin. A second approach is
to incorporate heparin by blending it with a polymer. In this
case, heparin is released by leaching or biodegradation of the
polymer (53). The third approach, such as that developed by
Carmeda, consists of heparin immobilization using end-point
attachment of heparin fragments to polyamine-dextran sulfate
layers that have absorbed on the stent surface (45,46). The
Medtronic (Hepamed) coating uses a similar approach where
unfractionated heparin is attached to a polyamine layer. This
layer has been previously covalently linked to a hydrogel
deposited on the stent surface (M Verhoeven, personal com-
munication). With the first two techniques, the release kinetics
and concentration of heparin determine the clinical lifetime of
the coating. With the last technology, the active site of heparin
remains free and heparin functions as a catalyzer to permit
repetitive inactivation of thrombin by antithrombin III. It has
been shown that immobilized heparin retains its ability to bind
thrombin for more than 4 months (8). Other anticoagulants
such as hirudin have been tested, although immobilized hiru-
din binds thrombin indefinitely and therefore a cycle of
inactivation cannot be entertained. Other research avenues
involve slow-release hirudin, immobilized fibrinolytic enzymes
or new antiplatelet agents such as glycoprotein IIb-IIIa inhib-
itors or glycoprotein Ib antagonists. Whether early reduction in
thrombogenicity will translate into reduction in neointima
formation and ultimately restenosis remains, however, to be
demonstrated.
Conclusions. Stents represent a major advance since the
introduction of coronary angioplasty. As stents may be im-
planted in smaller vessels and in more complex lesions in the
near future, the biocompatibility aspects will need to be further
analyzed and mastered. There is little doubt that the next
decade will witness the emergence of much less thrombogenic
coronary endoprostheses capable of being accepted and toler-
ated by the body environment. Indeed, the research in the
direction of reduction in stent thrombogenicity and in provid-
ing better tissue compatibility may have a significant impact on
stent effectiveness in a variety of clinical conditions and may
further expand the use of stents.
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